December 4, 2019

Biogen to Present Aducanumab Phase 3 Topline Results at Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019

Zurich, Switzerland – December 4, 2019 – Biogen announced it will host live webcasts of the presentation and a Q&A session related to aducanumab at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) annual congress in San Diego, California.

Thursday, December 5, 2019: 11:00 a.m. ET – Aducanumab Phase 3 topline results

Thursday, December 5, 2019: 5:00 p.m. ET – Investor Q&A call

Link to Biogen webcasts